Description
This guidance document applies to all biologic drug submissions where the sponsor seeks authorization for sale based on demonstrated similarity to a previously approved biologic drug and relies, in part, on prior information regarding that biologic drug in order to present a reduced clinical and non-clinical package as part of the submission.
Resources
| Name | Format | Description | Link |
|---|---|---|---|
| Guidance Document: Information and Submission Requirements for Biosimilar Biologic Drugs | HTML | Open resource | |
| Guidance Document: Information and Submission Requirements for Biosimilar Biologic Drugs | HTML | Open resource |